Articles scientifiques

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Auteurs : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Année : 2013
Journal : Lancet
Volume : 382(9897)
Pages : 1021-8

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.

Auteurs : Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart-Gebhart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Année : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(9)
Pages : 654-63

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Auteurs : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Année : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Auteurs : Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JL, de Azambuja E, El Saghir NS, Kaur R, McTiernan A, Partridge AH, Rowland JH, Singh-Carlson S, Vargo MM, Thompson B, Anderson BO
Année : 2013
Journal : Breast
Volume : 22(5)
Pages : 606-15

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Auteurs : Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M
Année : 2013
Journal : Breast Cancer Res. Treat.
Volume : 139(1)
Pages : 13-22

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.

Auteurs : Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart-Gebhart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA
Année : 2013
Journal : Curr Med Res Opin
Volume : 29(11)
Pages : 1463-73

Thoracic oncology: annual review.

Auteurs : Sculier JP, Berghmans T, Meert AP
Année : 2013
Journal : Rev Med Brux
Volume : 34(2)
Pages : 100-11

An atypical presentation of bronchial adenocarcinoma.

Auteurs : Langouo Fontsa M, CsToth I, Berghmans T, Feoli F, Meert AP
Année : 2013
Journal : Rev Med Brux
Volume : 34(3)
Pages : 181-3

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Auteurs : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Année : 2013
Journal : J Clin Invest
Volume : 123(7)
Pages : 2873-92

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Auteurs : Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M
Année : 2013
Journal : Lancet Oncol
Volume : 14(8)
Pages : 760-8

Single-access laparoscopic primary and incisional prosthetic hernia repair: first 50 patients.

Auteurs : Dapri G, Bruyns J, Paesmans M, Himpens J, Cadière GB
Année : 2013
Journal : Hernia
Volume : 17(5)
Pages : 619-26

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Auteurs : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Année : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pages : 1862-8

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Auteurs : Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, Boue F, Bron D, Feugier P, Haioun C, Offner F, Coiffier B
Année : 2013
Journal : Eur. J. Cancer
Volume : 49(4)
Pages : 904-910

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Auteurs : Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart-Gebhart M, Awada A
Année : 2013
Journal : J Chemother
Volume : 25(4)
Pages : 239-46

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Auteurs : Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(20)
Pages : 2586-92

Imbalance between supply and need of medical oncologists in Belgium

Auteurs : Dhondt V, Benahmed A, De Wever L, Dirix L, de Valeriola D
Année : 2013
Journal : Belgian J Medical Oncology
Volume : 7(2)
Pages : 38-45

Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia.

Auteurs : Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, Hamade E, Daher A, Hussein N, Eldirani R, Berri F, Vanhamme L, Burny A, Martiat P, Rouas R, Badran B
Année : 2013
Journal : J Transl Med
Volume : 11(1)
Pages : 31

Clinical practice-changing trials: the HERA study paradigm.

Auteurs : Zardavas D, Ades F, de Azambuja E
Année : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(11)
Pages : 1249-56

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

Auteurs : Von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, Awada A
Année : 2013
Journal : Crit Rev Oncol Hematol
Volume : 85(3)
Pages : 315-31